title: Is survival in myeloid malignancies really improving? A retrospective 15-year population-based study.
abstract: Myeloid malignancies (MMs) are heterogeneous groups of diseases which present different prognoses. Using data from the population-based Girona Cancer Registry, we estimated the relative survival (RS) rates and relative excess risk of death among patients with MMs in the province of Girona between 1994 and 2008. The 5-year RS rate was 49.7%, ranging from 20.2% for acute myeloid leukemia (AML) to 75.3% for myeloproliferative neoplasms (MPN). Marked differences in RS were observed when the age of patients was considered: an increase in RS was mainly found in younger patients with myelodysplastic syndromes and MPN. Furthermore, cases of chronic myeloid leukemia treated with imatinib had a significantly better outcome compared with those that were untreated. Despite the slight improvement in the survival rate of younger patients with AML, RS remained stable for 15 years, as no significant improvements were made in the management of the disease during that period.
authors: Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology, Girona Biomedical Research Institute (IdiBGi) , Girona , Spain.
authors: Gemma
authors: G
authors: Osca-Gelis
authors: Montserrat
authors: M
authors: Puig-Vives
authors: Marc
authors: M
authors: Saez
authors: David
authors: D
authors: Gallardo
authors: Natalia
authors: N
authors: Lloveras
authors: Ramon
authors: R
authors: Guàrdia
authors: Rafael
authors: R
authors: Marcos-Gragera
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D005260:Female; D019337:Hematologic Neoplasms / Q000175:diagnosis / Q000401:mortality* / Q000628:therapy; D006801:Humans; D053208:Kaplan-Meier Estimate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000401:mortality* / Q000628:therapy; D007951:Leukemia, Myeloid / Q000175:diagnosis / Q000401:mortality* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000175:diagnosis / Q000401:mortality* / Q000628:therapy; D009196:Myeloproliferative Disorders / Q000175:diagnosis / Q000401:mortality* / Q000628:therapy; D017063:Outcome Assessment, Health Care / Q000379:methods / Q000706:statistics & numerical data; D011159:Population Surveillance / Q000379:methods; D011379:Prognosis; D012042:Registries / Q000706:statistics & numerical data; D012189:Retrospective Studies; D013030:Spain; D015996:Survival Rate; D013997:Time Factors
keywords: Relative survival; acute myeloid leukemia; myelodysplastic syndromes; myelodysplastic/myeloproliferative neoplasms; myeloid malignancies; myeloproliferative neoplasms